AC
GCVRZ

Aristeia Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Aristeia Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-6,548,815
Closed -$13.2M – 82
2013
Q3 		$13.2M Sell
6,548,815
-345,313
-5% -$658K 0.84% 30
2013
Q2 		$13.1M Buy
+6,894,128
New +$12.1M 1.14% 22

Other funds holding GCVRZ

FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Aristeia Capital's GCVRZ Position: Q4 2013 in Review

Aristeia Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2013, closing a stake of 6,548,815 shares — an estimated $13.2M sold.

Aristeia Capital first reported a position in GCVRZ in Q2 2013 and held it in 2 quarters. The position peaked at $13.2M in Q3 2013. 130 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2013.

  • Aristeia Capital reported no remaining Sanofi Contingent Value Rights position as of Q4 2013 after selling out during the quarter.
  • Aristeia Capital sold 6,548,815 Sanofi Contingent Value Rights shares in Q4 2013, an estimated $13.2M.
  • Aristeia Capital first reported a position in Sanofi Contingent Value Rights in Q2 2013 and held it in 2 quarters.
  • Aristeia Capital's Sanofi Contingent Value Rights position peaked at $13.2M in Q3 2013.
  • 130 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2013.

Based on Aristeia Capital's 13F filing for Q4 2013, filed 13 Feb 2014.